Both have encouraging preclinical findings, but controlled human evidence for TBI is insufficient
A researcher administering 500mcg of BPC-157 via injection achieves approximately 400-475mcg of systemic absorption
The structural displacement visible on MRI will not change from BPC-157 treatment
Dec 29, 2025 Peptides absolutely expire, but shelf life varies dramatically based on form (lyophilized powder vs reconstituted liquid), storage conditions (freezer vs refrigerator vs room temperature), peptide type (some are more stable than others), and handling (contamination, light exposure, temperature fluctuations)
doi: 10.1067/mpd.2000.102940 40
Several methods are introduced to increase the half-life of GLP-1 including: (i) modifying peptides to make them resistant to cleavage by DPP-4, such as exenatide twice daily and lixisenatide, (ii) attaching free fatty acid side chains to liraglutide and semaglutide, which enhances their binding to plasma albumin thereby preventing renal filtration of GLP-1 and prolonging their action in vivo [36, 37], (iii) conjugation of albumin or the Fc fragment of IgG to GLP-1 molecule is used in albiglutide and dulaglutide [37, 38], (iv) development of modified nanoparticles for the controlled release of exenatide-LAR (long-acting release) that provide prolonged release of the peptide [39], and finally, (v) chemical permeation enhancers such as sodium salcaprozate (SNAC) could be utilized to overcome the low permeability and high enzymatic degradation of the gastrointestinal tract of GLP-1 analog that is administrated orally such as semaglutide [40]